Oppenheimer Asset Management Inc. reduced its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 71.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 460 shares of the medical instruments supplier’s stock after selling 1,142 shares during the period. Oppenheimer Asset Management Inc.’s holdings in C.R. Bard were worth $147,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of BCR. Farallon Capital Management LLC purchased a new position in C.R. Bard during the 2nd quarter valued at about $463,101,000. Alpine Associates Management Inc. bought a new stake in C.R. Bard during the 2nd quarter valued at about $265,663,000. Pentwater Capital Management LP bought a new stake in C.R. Bard during the 2nd quarter valued at about $139,088,000. York Capital Management Global Advisors LLC bought a new stake in C.R. Bard during the 2nd quarter valued at about $122,678,000. Finally, CNH Partners LLC bought a new stake in C.R. Bard during the 2nd quarter valued at about $116,100,000. 79.11% of the stock is owned by institutional investors.

Shares of C.R. Bard, Inc. (NYSE:BCR) opened at $333.83 on Wednesday. C.R. Bard, Inc. has a 12 month low of $218.72 and a 12 month high of $337.73. The company has a market cap of $24,332.20, a P/E ratio of 28.83, a PEG ratio of 2.55 and a beta of 0.52. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The firm had revenue of $989.80 million during the quarter, compared to analyst estimates of $990.64 million. During the same period in the previous year, the business posted $2.64 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. research analysts anticipate that C.R. Bard, Inc. will post 11.89 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date is Thursday, December 7th. This represents a $1.04 annualized dividend and a yield of 0.31%. C.R. Bard’s dividend payout ratio (DPR) is 13.70%.

A number of research firms have weighed in on BCR. ValuEngine lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen restated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research note on Friday, November 3rd. Barclays raised their price objective on shares of C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Finally, Jefferies Group restated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research note on Thursday, September 14th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a strong buy rating to the stock. C.R. Bard presently has an average rating of “Hold” and a consensus price target of $303.50.

In related news, insider Sharon M. Luboff sold 30,252 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $320.00, for a total transaction of $9,680,640.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Timothy P. Collins sold 8,388 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $322.00, for a total transaction of $2,700,936.00. The disclosure for this sale can be found here. Insiders have sold 210,032 shares of company stock valued at $68,777,261 over the last 90 days. 0.80% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/c-r-bard-inc-bcr-shares-sold-by-oppenheimer-asset-management-inc/1774318.html.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.